European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-03
DOI
10.1038/s41375-020-0776-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels
- (2020) Rüdiger Hehlmann et al. BLOOD
- FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial
- (2020) Mhairi Copland et al. BLOOD
- Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
- (2020) Young Rok Do et al. BRITISH JOURNAL OF HAEMATOLOGY
- The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
- (2019) Michele Baccarani et al. LEUKEMIA
- The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
- (2019) Masa Lasica et al. LEUKEMIA & LYMPHOMA
- Risks and challenges of CML management during pregnancy: Looking for a balanced decision
- (2019) Ekaterina Chelysheva et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry
- (2019) Anna Lübking et al. BONE MARROW TRANSPLANTATION
- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
- (2019) Aytug Kizilors et al. Lancet Haematology
- De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
- (2019) Richard E Clark et al. Lancet Haematology
- Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
- (2019) Kiran Naqvi et al. CANCER
- The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission
- (2019) Claire Andrews et al. LEUKEMIA & LYMPHOMA
- The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
- (2019) Claire N Andrews et al. Lancet Haematology
- Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
- (2019) Ya-Chen Tina Shih et al. Lancet Haematology
- Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial
- (2019) Gabriele Gugliotta et al. BLOOD
- Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
- (2019) B. Douglas Smith et al. BLOOD
- Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
- (2019) Timothy P. Hughes et al. BLOOD
- Epidemiologic Signatures in Cancer
- (2019) H. Gilbert Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
- (2019) Simona Soverini et al. BLOOD
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meeting the needs of CML patients in resource-poor countries
- (2019) Hemant Malhotra et al. Hematology-American Society of Hematology Education Program
- Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
- (2018) Dong-Wook Kim et al. ANNALS OF HEMATOLOGY
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients
- (2018) Inge G. P. Geelen et al. LEUKEMIA
- Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
- (2018) Gita Thanarajasingam et al. Lancet Haematology
- Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
- (2018) Ekaterina Chelysheva et al. Mediterranean Journal of Hematology and Infectious Diseases
- Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
- (2018) Timothy P. Hughes et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2018) Jerald P. Radich et al. Journal of the National Comprehensive Cancer Network
- Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value
- (2018) Juliana E. Hidalgo-Lόpez et al. CANCER
- Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia
- (2018) Elisabetta Abruzzese et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
- (2018) Christian Michel et al. HAEMATOLOGICA
- A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
- (2018) Alejandro Zulbaran-Rojas et al. Cancer Medicine
- Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis
- (2017) Leonardo Campiotti et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
- (2017) T P Hughes et al. LEUKEMIA
- Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
- (2017) A Hochhaus et al. LEUKEMIA
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
- (2017) R Hehlmann et al. LEUKEMIA
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Issues of Imatinib and Pregnancy Outcome
- (2017) Jane Apperley Journal of the National Comprehensive Cancer Network
- Management of CML-blast crisis
- (2016) Rüdiger Hehlmann et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) W. Wang et al. BLOOD
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
- (2016) Stina Söderlund et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia
- (2016) Aaron N. Winn et al. JOURNAL OF CLINICAL ONCOLOGY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
- (2016) William V. Padula et al. JNCI-Journal of the National Cancer Institute
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
- (2016) Jeffrey H Lipton et al. LANCET ONCOLOGY
- Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
- (2016) H Hjorth-Hansen et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- The concept of treatment-free remission in chronic myeloid leukemia
- (2016) S Saußele et al. LEUKEMIA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment
- (2016) Franck-Emmanuel Nicolini et al. LEUKEMIA RESEARCH
- Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
- (2016) David J. Dorer et al. LEUKEMIA RESEARCH
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors
- (2016) F. Efficace et al. Hematology-American Society of Hematology Education Program
- Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States
- (2016) William V. Padula et al. JNCI-Journal of the National Cancer Institute
- The impact of dasatinib on pregnancy outcomes
- (2015) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Chronic myeloid leukemia: Second-line drugs of choice
- (2015) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
- (2015) Alice Fabarius et al. ANNALS OF HEMATOLOGY
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
- (2015) S. Saussele et al. BLOOD
- Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
- (2015) Jianxiang Wang et al. BLOOD
- Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012
- (2015) Noortje Thielen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
- (2015) A Gratwohl et al. LEUKEMIA
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
- (2015) F Castagnetti et al. LEUKEMIA
- The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
- (2015) V S Hoffmann et al. LEUKEMIA
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
- (2015) A Hochhaus et al. LEUKEMIA
- Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
- (2015) N C P Cross et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
- (2015) Franck E Nicolini et al. Lancet Haematology
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
- (2014) T. P. Hughes et al. BLOOD
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
- (2014) P. Valent et al. BLOOD
- Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules
- (2014) Joëlle Guilhot et al. CANCER
- Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
- (2014) Henrik Hjorth-Hansen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden
- (2014) M. Baccarani et al. HAEMATOLOGICA
- Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
- (2014) Michael Lauseker et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
- (2014) Johan Richter et al. JOURNAL OF CLINICAL ONCOLOGY
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
- (2013) Paolo Strati et al. CANCER
- Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
- (2013) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
- (2012) M Talpaz et al. LEUKEMIA
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Standardized definitions of molecular response in chronic myeloid leukemia
- (2012) N C P Cross et al. LEUKEMIA
- Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
- (2012) Kristin M. Phillips et al. SUPPORTIVE CARE IN CANCER
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
- (2011) D. Milojkovic et al. HAEMATOLOGICA
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
- (2011) V Grossmann et al. LEUKEMIA
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Standardisation of molecular monitoring for chronic myeloid leukaemia
- (2009) Nicholas C.P. Cross BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started